Rapid Finger-Prick test could help shield cancer patients from COVID-19

NCT ID NCT04492410

First seen Jun 27, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tested a quick finger-prick blood test to see if cancer patients had been infected with COVID-19 in the past. Researchers enrolled 214 adults being treated for cancer. The goal was to find out how many had antibodies, including those without symptoms, to help clinics keep infected and non-infected patients apart and plan safer cancer care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
rapid serological test (finger-prick blood test)
What this could lead to
If successful, this screening method could help cancer clinics quickly identify patients who have had COVID-19, allowing safer separation of infected and non-infected patients during treatment.
What could go wrong
This was a small, completed study focused on measuring infection rates, not on treating disease. The rapid test may be less accurate than standard lab tests, and results may not apply to all cancer patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Antoine Lacassagne

    Nice, France, 06189, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.